URGN - UroGen Pharma Quarterly EPS earnings growth

Brandmark of UroGen Pharma (URGN)

UroGen Pharma Ltd. (URGN) is transitioning from the research phase to expanding its commercial presence in urological oncology. Business growth is driven by the success of Jelmyto and the approval of UGN-102, while maintaining strict cost controls. The implementation of unique long-acting drugs ensures stability. The quarterly EPS growth rate on GURU.Markets reflects profit dynamics, where the current figure is 95.10.

URGN: UroGen Pharma Quarterly EPS earnings growth 07/04/2022 - 11/17/2026

Analytical breakdowns for UroGen Pharma Ltd.

- market value and analyst target forecast:
Fundamental company analysis:urogen.com - URGN
Manufactured product of UroGen Pharma Corp

Quarterly EPS growth reflects the dynamics of net income per share, measuring the efficiency of capital generation for shareholders. This metric is calculated as the percentage change in earnings between the current period and the same period last year. By analyzing the quarterly EPS growth vector, an investor determines the business's operational turnaround phase. For UroGen Pharma Ltd. (URGN), this indicator marks the success of innovations in uro-oncology. High expenditures on scientific personnel and achievement bonuses directly impact the final profitability.

Analysis of competing companies

ONC: Quarterly EPS earnings growth|Halozyme Inc. - Year-over-year earnings per one share growth for the last 12 months|RVMD (Revolution Medicines Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Ascentage Pharma Group AAPG|Quarterly EPS earnings growth CGON|Year-over-year earnings per share growth for the last twelve months BCAX (Bicara Therapeutics)|Quarterly EPS earnings growth PSNL (personalis.com)|Year-over-year earnings per one share growth for the last 12 months ERAS|DCTH - Year-over-year earnings per share growth for the last twelve months|Y-mAbs Therapeutics (YMAB) - Year-over-year net earnings per share growth for the last 12 months|AURA: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months CADL|Year-over-year earnings per share growth for the last twelve months Accuray Inc.|SELLAS Life Sciences Group (SLS) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ACTU (Actuate Therapeutics, Inc)|Year-over-year net earnings per share change for the last twelve months Citius Oncology|TuHURA Biosciences, Inc. - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Protara TARA|fatetherapeutics.com - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Aadi Bioscience|TCRX: Quarterly EPS earnings growth|CSBR - Year-over-year net earnings per share change for the last twelve months|XBIT (XBiotech) - Quarterly EPS earnings growth|CVM: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth OSTX|RADX (Radiopharm Theranostics Limited) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ARTV (Artiva Biotherapeutics, Inc.)|Year-over-year earnings per one share growth for the last 12 months ANL|VERU: Year-over-year net earnings per share growth for the last 12 months|TPST - Quarterly EPS earnings growth|XLO (xiliotx.com) - Year-over-year net earnings per share growth for the last 12 months|Renovaro Biosciences - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months MURA|Year-over-year earnings per share growth for the last twelve months KAPA|Year-over-year net earnings per share growth for the last 12 months OKUR (OnKure Therapeutics Inc)|Quarterly EPS earnings growth CytoMed (GDTC)|Year-over-year earnings per share growth for the last twelve months curis.com CRIS|APLM (Apollomics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|Tharimmune Corporation - Quarterly EPS earnings growth|ADVB (advanbiomed.com) - Year-over-year earnings per share growth for the last 12 months|Genprex, Inc (GNPX) - Year-over-year earnings per share growth for the last twelve months|CLDI: Year-over-year earnings per share growth rate for the last twelve months|SBFM (Sunshine Biopharma, Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months XBIO (Xenetic Biosciences)|Quarterly EPS earnings growth SLRX|Purple Biotech - Year-over-year earnings per share growth for the last 12 months|American Oncology Network - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months BGNE|CKPT - Year-over-year earnings per share growth for the last twelve months|Elevation Oncology (ELEV) - Year-over-year net earnings per share growth for the last 12 months|ICAD: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Ikena Oncology Inc.|NTBL (Notable Labs Ltd) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Viracta Therapeutics (VIRX)|Year-over-year earnings per share growth for the last twelve months MorphoSys Corporation (MOR)|NAYA (NAYA Biosciences) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth AAPGV (Ascentage)